Is IMRX or PLRX more profitable?

Immuneering's return on equity of -27.15% beat Pliant Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -27.15% -25.75% Pliant Therapeutics N/A -52.17% -40.46%

Is LRMR or PLRX more profitable?

Pliant Therapeutics' return on equity of -52.17% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -137.39% -97.65% Pliant Therapeutics N/A -52.17% -40.46%

Is LXEO or PLRX more profitable?

Lexeo Therapeutics' return on equity of -41.85% beat Pliant Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -41.85% -38.03% Pliant Therapeutics N/A -52.17% -40.46%

Do analysts rate NLTX or PLRX?

Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 209.92%. Given Pliant Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Pliant Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is NLTX or PLRX more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Pliant Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Pliant Therapeutics N/A -52.17% -40.46%

Is IFRX or PLRX more profitable?

Pliant Therapeutics' return on equity of -52.17% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Pliant Therapeutics N/A -52.17% -40.46%

Pliant Therapeutics (PLRX) Competitors

$0.89 -0.07 (-7.64%)

Closing price 03:59 PM Eastern

Extended Trading

$0.90 +0.00 (+0.34%)

As of 04:06 PM Eastern

Compare

PLRX vs. IMRX, LRMR, LXEO, NLTX, and IFRX

Should you buy Pliant Therapeutics stock or one of its competitors? Pliant Therapeutics's main competitors and comparable companies include Immuneering (IMRX), Larimar Therapeutics (LRMR), Lexeo Therapeutics (LXEO), Neoleukin Therapeutics (NLTX), and InflaRx (IFRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pliant Therapeutics compare to Immuneering?

Immuneering (NASDAQ:IMRX) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

Immuneering has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

Immuneering has higher earnings, but lower revenue than Pliant Therapeutics. Immuneering is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
Pliant Therapeutics	$1.58M	37.94	-$149.34M	-$1.49	N/A

Immuneering's return on equity of -27.15% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-27.15%	-25.75%
Pliant Therapeutics	N/A	-52.17%	-40.46%

67.7% of Immuneering shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 14.9% of Immuneering shares are held by company insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Immuneering presently has a consensus price target of $15.71, indicating a potential upside of 341.41%. Pliant Therapeutics has a consensus price target of $3.00, indicating a potential upside of 209.92%. Given Immuneering's stronger consensus rating and higher possible upside, research analysts plainly believe Immuneering is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Pliant Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Immuneering had 2 more articles in the media than Pliant Therapeutics. MarketBeat recorded 3 mentions for Immuneering and 1 mentions for Pliant Therapeutics. Immuneering's average media sentiment score of 1.05 equaled Pliant Therapeutics'average media sentiment score.

Company	Overall Sentiment
Immuneering	Positive
Pliant Therapeutics	Positive

Summary

Immuneering beats Pliant Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Pliant Therapeutics compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Pliant Therapeutics has higher revenue and earnings than Larimar Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
Pliant Therapeutics	$1.58M	37.94	-$149.34M	-$1.49	N/A

Larimar Therapeutics currently has a consensus target price of $10.33, indicating a potential upside of 378.40%. Pliant Therapeutics has a consensus target price of $3.00, indicating a potential upside of 209.92%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Larimar Therapeutics is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Pliant Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 4.0% of Larimar Therapeutics shares are owned by insiders. Comparatively, 8.7% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Larimar Therapeutics had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 2 mentions for Larimar Therapeutics and 1 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 1.05 beat Larimar Therapeutics' score of 0.91 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Larimar Therapeutics	Positive
Pliant Therapeutics	Positive

Larimar Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

Pliant Therapeutics' return on equity of -52.17% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
Pliant Therapeutics	N/A	-52.17%	-40.46%

Summary

Pliant Therapeutics beats Larimar Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Pliant Therapeutics compare to Lexeo Therapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

In the previous week, Lexeo Therapeutics had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 2 mentions for Lexeo Therapeutics and 1 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 1.05 beat Lexeo Therapeutics' score of 0.60 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lexeo Therapeutics	Positive
Pliant Therapeutics	Positive

Lexeo Therapeutics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 2.0% of Lexeo Therapeutics shares are held by insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Lexeo Therapeutics has higher earnings, but lower revenue than Pliant Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A
Pliant Therapeutics	$1.58M	37.94	-$149.34M	-$1.49	N/A

Lexeo Therapeutics' return on equity of -41.85% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-41.85%	-38.03%
Pliant Therapeutics	N/A	-52.17%	-40.46%

Lexeo Therapeutics currently has a consensus price target of $18.13, suggesting a potential upside of 561.50%. Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 209.92%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Lexeo Therapeutics is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Pliant Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lexeo Therapeutics beats Pliant Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Pliant Therapeutics compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Neoleukin Therapeutics has higher earnings, but lower revenue than Pliant Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Pliant Therapeutics	$1.58M	37.94	-$149.34M	-$1.49	N/A

In the previous week, Pliant Therapeutics had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for Pliant Therapeutics and 0 mentions for Neoleukin Therapeutics. Pliant Therapeutics' average media sentiment score of 1.05 beat Neoleukin Therapeutics' score of 0.00 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Pliant Therapeutics	Positive

Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Neoleukin Therapeutics' return on equity of -37.22% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Pliant Therapeutics	N/A	-52.17%	-40.46%

Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 209.92%. Given Pliant Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pliant Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Pliant Therapeutics beats Neoleukin Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Pliant Therapeutics compare to InflaRx?

InflaRx (NASDAQ:IFRX) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

In the previous week, InflaRx had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 2 mentions for InflaRx and 1 mentions for Pliant Therapeutics. InflaRx's average media sentiment score of 1.60 beat Pliant Therapeutics' score of 1.05 indicating that InflaRx is being referred to more favorably in the media.

Company	Overall Sentiment
InflaRx	Very Positive
Pliant Therapeutics	Positive

42.4% of InflaRx shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

InflaRx presently has a consensus price target of $7.43, indicating a potential upside of 379.26%. Pliant Therapeutics has a consensus price target of $3.00, indicating a potential upside of 209.92%. Given InflaRx's stronger consensus rating and higher probable upside, analysts clearly believe InflaRx is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Pliant Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pliant Therapeutics' return on equity of -52.17% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Pliant Therapeutics	N/A	-52.17%	-40.46%

InflaRx has a beta of 2.59, indicating that its share price is 159% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

InflaRx has higher earnings, but lower revenue than Pliant Therapeutics. InflaRx is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	7,614.12	-$51.63M	-$0.58	N/A
Pliant Therapeutics	$1.58M	37.94	-$149.34M	-$1.49	N/A

Summary

InflaRx beats Pliant Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Pliant Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLRX vs. The Competition

Export

Metric	Pliant Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$55.36M	$3.90B	$7.28B	$12.92B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-0.60	12.49	275.28	25.28
Price / Sales	35.04	1,151.22	562.38	78.55
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	0.30	16.55	10.52	5.92
Net Income	-$149.34M	-$22.69M	$3.50B	$381.04M
7 Day Performance	-9.70%	-6.66%	-4.32%	-4.41%
1 Month Performance	-22.26%	-14.41%	-8.66%	-7.30%
1 Year Performance	-40.79%	5.91%	1.94%	-5.04%

Pliant Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLRX Pliant Therapeutics	1.7141 of 5 stars	$0.89 -7.6%	$3.00 +235.6%	-35.0%	$55.36M	$1.58M	N/A	49	Positive News
IMRX Immuneering	2.7116 of 5 stars	$3.68 -4.8%	$15.71 +327.6%	-42.0%	$237.44M	N/A	N/A	57	Positive News
LRMR Larimar Therapeutics	2.5666 of 5 stars	$2.27 -10.5%	$10.33 +356.2%	-49.2%	$237.37M	N/A	N/A	71
LXEO Lexeo Therapeutics	3.5215 of 5 stars	$2.82 -7.4%	$18.13 +543.9%	-66.6%	$230.89M	N/A	N/A	59
NLTX Neoleukin Therapeutics	N/A	$24.44 -7.4%	N/A	-19.1%	$229.69M	N/A	N/A	90	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLRX) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pliant Therapeutics (PLRX) Competitors

PLRX vs. IMRX, LRMR, LXEO, NLTX, and IFRX

How does Pliant Therapeutics compare to Immuneering?

Summary

How does Pliant Therapeutics compare to Larimar Therapeutics?

Summary

How does Pliant Therapeutics compare to Lexeo Therapeutics?

Summary

How does Pliant Therapeutics compare to Neoleukin Therapeutics?

Summary

How does Pliant Therapeutics compare to InflaRx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pliant Therapeutics (PLRX) Competitors

PLRX vs. IMRX, LRMR, LXEO, NLTX, and IFRX

How does Pliant Therapeutics compare to Immuneering?

Which has more risk & volatility, IMRX or PLRX?

Which has preferable earnings and valuation, IMRX or PLRX?

Is IMRX or PLRX more profitable?

Do institutionals and insiders believe in IMRX or PLRX?

Do analysts recommend IMRX or PLRX?

Does the media refer more to IMRX or PLRX?

Summary

How does Pliant Therapeutics compare to Larimar Therapeutics?

Which has preferable valuation & earnings, LRMR or PLRX?

Do analysts rate LRMR or PLRX?

Do insiders and institutionals believe in LRMR or PLRX?

Does the media refer more to LRMR or PLRX?

Which has more volatility and risk, LRMR or PLRX?

Is LRMR or PLRX more profitable?

Summary

How does Pliant Therapeutics compare to Lexeo Therapeutics?

Does the media favor LXEO or PLRX?

Which has more risk and volatility, LXEO or PLRX?

Do insiders & institutionals hold more shares of LXEO or PLRX?

Which has stronger earnings & valuation, LXEO or PLRX?

Is LXEO or PLRX more profitable?

Do analysts prefer LXEO or PLRX?

Summary

How does Pliant Therapeutics compare to Neoleukin Therapeutics?

Which has stronger valuation & earnings, NLTX or PLRX?

Does the media refer more to NLTX or PLRX?

Which has more risk & volatility, NLTX or PLRX?

Do institutionals & insiders hold more shares of NLTX or PLRX?

Is NLTX or PLRX more profitable?

Do analysts rate NLTX or PLRX?

Summary

How does Pliant Therapeutics compare to InflaRx?

Does the media refer more to IFRX or PLRX?

Do institutionals & insiders believe in IFRX or PLRX?

Do analysts recommend IFRX or PLRX?

Is IFRX or PLRX more profitable?

Which has more volatility and risk, IFRX or PLRX?

Which has preferable valuation & earnings, IFRX or PLRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools